Safety of Lupin's Ranibizumab (Ranieyes) established in Large-Scale Multicenter Study with 2194 injections in 1401 eyes

Real-World Indian Data Confirms Safety of Lupin's Ranieyes for various Chorioretinal Vascular Disease

Ranibizumab (Ranieyes) is a safe intravitreal antivascular endothelial growth factor (Anti -VEGF) agent across various chorioretinal vascular diseases, a recent Large Scale multicenter Indian study has concluded. This study has been published in the November issue of the Ophthalmology and Therapy Journal.

Ranibizumab is a commonly used anti-VEGF therapy to treat chorioretinal vascular diseases. The approved indications for ranibizumab include neovascular age-related macular degeneration (n-AMD), diabetic macular edema (DME), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO).

Ranieyes is a biosimilar developed by Lupin Pharmaceuticals in India.

To study the safety profile of Ranieyes in multiple eye conditions, a retrospective, consecutive, interventional, uncontrolled multicenter study was conducted using data from three hospital networks in India. The study included 636 males and 533 females with different diagnoses and a mean age of 58.63. It covered 1401 eyes and 2194 Ranieyes injections administered between June 2022 and November 2023, with a minimum follow-up period of six months to assess ocular and systemic adverse events.